124 patents
Utility
Methods and Compositions for Use of Therapeutic T Cells In Combination with Kinase Inhibitors
18 Jan 24
The present disclosure relates to methods, compositions and uses involving immunotherapies and inhibitors of a target protein tyrosine kinase in which the kinase is not IL-2-inducible T cell kinase (ITK) and/or is selected from Bruton's tyrosine kinase (BTK), tec protein tyrosine kinase (TEC), BMX non-receptor tyrosine kinase (Etk), TXK tyrosine kinase (TXK) and/or receptor tyrosine-protein kinase ErbB4 (ErbB4).
Michael Ports, Jim Qin, Ruth Salmon, Oleksandr Baturevych
Filed: 17 Jan 23
Utility
Antibodies and Chimeric Antigen Receptors Specific for CD19
18 Jan 24
Provided are CD19 binding molecules, including anti-CD19 antibodies, including antibody fragments such as single-chain fragments, and chimeric receptors including the antibodies, such as chimeric antigen receptors (CARs).
Yan CHEN, Steven M. Shamah, Csaba Pazmany, Jui DUTTA-SIMMONS
Filed: 5 Jul 23
Utility
Anti-idiotypic Antibodies Against ANTI-CD19 Antibodies
18 Jan 24
Provided herein are anti-idiotype antibodies that specifically recognize anti-CD19 antibody moieties, in particular, anti-CD19 antibody moieties present in recombinant receptors, including chimeric antigen receptors (CARs).
Collin HAUSKINS, Mark D. HEIPEL, Claire L. SUTHERLAND, Taher SATHALIYA, Jeff SMITH
Filed: 29 Jul 17
Utility
Methods for Transduction and Cell Processing
11 Jan 24
Provided are methods, systems, and kits for cell processing, e.g., for therapeutic use, such as for adoptive cell therapy.
Ryan L. CRISMAN, Chris RAMSBORG, Travis WOOD
Filed: 21 Sep 23
Utility
Cells Expressing a Chimeric Receptor from a Modified Invariant CD3 Immunoglobulin Superfamily Chain Locus and Related Polynucleotides and Methods
14 Dec 23
Provided herein are engineered T cells, expressing a chimeric receptor comprising an antigen-binding domain fused to an endogenous invariant CD3 chain of the immunoglobulin superfamily (invariant CD3-IgSF).
Mateusz Pawel POLTORAK, Lothar GERMEROTH, Christian STEMBERGER
Filed: 3 Nov 21
Utility
Car T Cell Therapy In Patients Who Have Had Prior Anti-cancer Alkylator Therapy
14 Dec 23
Provided herein are uses of chimeric antigen receptors (CARs) for treating a tumor or a cancer (such as B cell related cancer, e.g., multiple myeloma).
Julie Ann RYTLEWSKI, Afshin MASHADI-HOSSEIN, Timothy CAMPBELL, Jaymes FULLER
Filed: 3 Nov 21
Utility
Antibodies and chimeric antigen receptors specific for CD19
28 Nov 23
Provided are CD19 binding molecules, including anti-CD19 antibodies, including antibody fragments such as single-chain fragments, and chimeric receptors including the antibodies, such as chimeric antigen receptors (CARs).
Yan Chen, Steven M. Shamah, Csaba Pazmany, Jui Dutta-Simmons
Filed: 2 Dec 19
Utility
Epigenetic analysis of cell therapy and related methods
21 Nov 23
Provided herein are methods of identifying genomic region(s) predictive of an outcome of treatment with a cell therapy and/or of a phenotype of function of the cells.
Mark L. Bonyhadi, David G. Kugler, Timothy G. Johnstone, Ronald James Hause, Jr., Lucas J. Thompson, Ryan P. Larson
Filed: 10 Jan 18
Utility
Antibodies and Chimeric Antigen Receptors Specific for B-cell Maturation Antigen
16 Nov 23
Provided herein are BCMA-binding molecules, including anti-BCMA antibodies and antigen-binding fragments thereof such as heavy chain variable (VH) regions and single-chain antibody fragments, and chimeric receptors comprising the anti-BCMA binding molecules such as chimeric antigen receptors (CARs).
Blythe D. SATHER, Steven M. SHAMAH, Yan CHEN, Rebecca WU, Collin HAUSKINS, Csaba PAZMANY, Jui DUTTA-SIMMONS, Kimberly HARRINGTON
Filed: 7 Apr 23
Utility
Methods and compositions related to toxicity associated with cell therapy
14 Nov 23
Provided are methods, kits and compositions related to toxicity associated with administration of cell therapy for the treatment of diseases or conditions, e.g., cancer, including methods for use in predicting and treating a toxicity.
He Li, Mark J. Gilbert, David Maloney, Stanley R. Riddell, Cameron J. Turtle
Filed: 2 Dec 16
Utility
Methods for transduction and cell processing
31 Oct 23
Provided are methods, systems, and kits for cell processing, e.g., for therapeutic use, such as for adoptive cell therapy.
Ryan L. Crisman, Chris Ramsborg, Travis Wood
Filed: 14 Aug 19
Utility
Methods for assessing cell surface glycosylation
24 Oct 23
Provided herein are methods for assessing cell surface glycans, e.g., N-glycans, by assessing a sample of released surface glycans, and determining the presence, absence, or level of glycans present in the sample.
Paul Ken Kodama, Tom Kowski, Mima Mujacic, Kenneth Mayo Prentice
Filed: 13 Apr 18
Utility
Engineered B cells and related compositions and methods
24 Oct 23
Provided herein are engineered B cells, such as for adoptive cell therapy.
Hyam I. Levitsky
Filed: 30 Nov 17
Utility
Anti-idiotypic Antibodies to ROR1-TARGETED Binding Domains and Related Compositions and Methods
12 Oct 23
Provided are anti-idiotype antibodies that specifically recognize anti-ROR1 antibody moieties, in particular, anti-ROR1 antibody moieties present in recombinant receptors, including chimeric antigen receptors (CARs).
Collin HAUSKINS, Catherine SIERRA, Andreia COSTA, Yeonjoo OH
Filed: 4 Aug 21
Utility
Methods and Compositions for Dosing In Adoptive Cell Therapy
14 Sep 23
Provided are methods for administering multiple doses of cells, such as T cells, to subjects for cell therapy.
Mark J. GILBERT
Filed: 22 Mar 23
Utility
T Cell Receptors and Engineered Cells Expressing Same
17 Aug 23
Provided herein are binding molecules, such as those that recognize or bind a peptide epitope of a cancer antigen, such as expressed on a cancer cell, including cells infected with human papilloma virus (HPV) or that contain HPV DNA sequences and/or those that recognize or bind a peptide epitope of HPV 16 E6 or E7, in the context of a major histocompatibility complex (MHC) molecule.
Stephen Jacob GOLDFLESS, Brian BELMONT, Cameron BRANDT, Alexandra CROFT, David Jeffrey HUSS
Filed: 30 Jun 22
Utility
Reagents for Expanding Cells Expressing Recombinant Receptors
3 Aug 23
The present disclosure provides compositions and methods for stimulating, enriching, expanding, and/or activating engineered cells that express a recombinant receptor, e.g., a chimeric antigen receptor.
Collin HAUSKINS, Scott HUSSELL, Catherine SIERRA, Melissa WORKS
Filed: 28 Jul 18
Utility
Methods and Uses Related to Cell Therapy Engineered with a Chimeric Antigen Receptor Targeting B-cell Maturation Antigen
18 May 23
Provided are methods and uses related to adoptive cell therapy involving the administration of doses of cells, such as T cells, for treating disease and conditions, including certain plasma cell malignancies.
Mariana Cota STIRNER, Mirna MUJACIC, Todd DEVRIES
Filed: 9 Apr 21
Utility
Articles of Manufacture and Methods for Treatment Using Adoptive Cell Therapy
18 May 23
Provided are adoptive cell therapy methods involving the administration of doses of cells for treating disease and conditions, including certain B cell malignancies.
Tina ALBERTSON, Brian CHRISTIN, Jacob Randolph GARCIA, Christopher Glen RAMSBORG, Claire L. SUTHERLAND, Clinton WEBER, Rachel K. YOST, Mark J. GILBERT, He LI
Filed: 22 Jun 22
Utility
Methods, Compositions and Components for CRISPR-CAS9 Editing of CBLB In T Cells for Immunotherapy
4 May 23
CRISPR/CAS-related genome editing systems, compositions and methods for targeting the CBLB locus, as well as cells edited using these systems, compositions and methods are provided.
Andreia S. COSTA, Jason David FONTENOT, Fred HARBINSKI, Gordon Grant WELSTEAD, Chris WILSON
Filed: 5 Nov 18